Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-000979
Filing Date
2025-02-14
Accepted
2025-02-14 09:00:17
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8650
  Complete submission text file 0000902664-25-000979.txt   10392
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Subject) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92700 | Film No.: 25623695
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607
Business Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

EIN.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A